Breast cancer detection and survival among women with cosmetic breast implants: systematic review and meta-analysis of observational studies

Abstract

Objectives To evaluate whether the stage distribution among women diagnosed as having breast cancer differs between those who have received breast implants for cosmetic purposes and those with no implants and to evaluate whether cosmetic breast augmentation before the detection of breast cancer is a predictor of post-diagnosis survival.Design Systematic review of observational studies with two meta-analyses.Data sources Systematic search of the literature published before September 2012 conducted in Medline, Embase, Global health, CINAHL, IPAB, and PsycINFO.Study selection Eligible publications were those that included women diagnosed as having breast cancer and who had had augmentation mammaplasty for cosmetic purposes. ResultsThe overall odds ratio of the first meta-analysis based on 12 studies was 1.26 (95% confidence interval 0.99 to 1.60; P=0.058; I 2 =35.6%) for a non-localized stage of breast cancer at diagnosis comparing women with implants who had breast cancer and women without implants who had breast cancer. The second meta-analysis, based on five studies, evaluated the relation between cosmetic breast implantation and survival. This meta-analysis showed reduced survival after breast cancer among women who had implants compared with those who did not (overall hazard ratio for breast cancer specific mortality 1.38, 95% confidence interval 1.08 to 1.75). ConclusionsThe research published to date suggests that cosmetic breast augmentation adversely affects the survival of women who are subsequently diagnosed as having breast cancer. These findings should be interpreted with caution, as some studies included in the meta-analysis on survival did not adjust for potential confounders. Further investigations are warranted regarding diagnosis and prognosis of breast cancer among women with breast implants.

The Response of Breast Cancer Cells to Mesenchymal Stem Cells

“…This represents an important reassurance about the use of breast implants, which are periodically the subject of doubts about collateral effects, as recently investigated by Lavigne and colleagues. 33 Further studies are required to better understand mechanisms underlying inflammation, mesenchymal stem cells, and paracrine effects and to evaluate potential correlations with clinic outcomes. …”

Downregulation of Ras GTPase-activating protein 1 is associated with poor survival of breast invasive ductal carcinoma patients

“…Breast cancer is the most significant worldwide health concern for females, accounting for the leading cause of cancer incidence and the second mortality rate in 2008 (1)(2)(3). In spite of advancements in early detection, treatment options, and prevention strategies for controlling breast cancer, a high percentage of breast cancer cases continue to progress, metastasize, and eventually cause patients to succumb to the disease.…”

Kosmetiske brystimplantater og brystkreft

“…Våre resultater knyttet til histopatologisk karakteristikk samsvarer med funn i andre studier (9, 14, 24−27), men det er også studier som ikke dokumenterer denne forskjellen (7,26). En oversiktsartikkel fra 2013 viser at kvinner med implantat oftere fikk påvist ikkelokalisert sykdom og at de hadde høyere brystkreftspesifikk dødelighet enn kvinner uten implantat (27). Dette kan tale for at kvinner med implantat kan ha nytte av tilleggsundersøkelse med ultralyd eller MR. Men, hverken ultralyd eller MR påviser mikrokalk og er derfor ikke tilstrekkelig alene for å påvise eller utelukke duktalt karsinom in situ.…”